Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityNon-Current AssetsOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lipocine (LPCN) Cash & Equivalents (2016 - 2025)

Historic Cash & Equivalents for Lipocine (LPCN) over the last 13 years, with Q3 2025 value amounting to $15.1 million.

  • Lipocine's Cash & Equivalents fell 2401.06% to $15.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $15.1 million, marking a year-over-year decrease of 2401.06%. This contributed to the annual value of $21.6 million for FY2024, which is 171.56% down from last year.
  • As of Q3 2025, Lipocine's Cash & Equivalents stood at $15.1 million, which was down 2401.06% from $17.6 million recorded in Q2 2025.
  • Lipocine's Cash & Equivalents' 5-year high stood at $45.9 million during Q2 2021, with a 5-year trough of $15.1 million in Q3 2025.
  • Over the past 5 years, Lipocine's median Cash & Equivalents value was $24.5 million (recorded in 2024), while the average stood at $27.9 million.
  • In the last 5 years, Lipocine's Cash & Equivalents soared by 23134.65% in 2021 and then plummeted by 3153.95% in 2023.
  • Quarter analysis of 5 years shows Lipocine's Cash & Equivalents stood at $45.8 million in 2021, then dropped by 29.93% to $32.1 million in 2022, then plummeted by 31.54% to $22.0 million in 2023, then decreased by 1.72% to $21.6 million in 2024, then plummeted by 30.2% to $15.1 million in 2025.
  • Its Cash & Equivalents stands at $15.1 million for Q3 2025, versus $17.6 million for Q2 2025 and $19.7 million for Q1 2025.